Navigation Links
Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
Date:7/3/2008

BIOCITECH, France, July 3 /PRNewswire-FirstCall/ -- Cellectis SA today announced the signature of an agreement with Regeneron Pharmaceuticals, Inc. over the use of Cellectis' patents covering certain uses of homologous recombination for the generation of innovative human therapies, including the development of fully human monoclonal antibodies. As part of the agreement, Cellectis will receive an upfront of 12,450,000$ from Regeneron. In addition, Regeneron will invest in Cellectis' equity.

The agreement resolves a dispute between the two companies related to the interpretation of a license agreement entered into by and between Cellectis and Regeneron in December 2003 pursuant to which Regeneron licensed certain patents and patent applications relating to a process for the specific replacement of a copy of a gene in the receiver genome by homologous recombination. Pursuant to the agreement, Regeneron will make an up-front payment to Cellectis in the amount of $12,450,000. In addition, Regeneron will pay Cellectis a low single-digit royalty based on revenue received by Regeneron from any future licenses or sales of Regeneron's VelociGene(R) or VelocImmune(R) products and services. No royalties are payable with respect to Regeneron's VelocImmune license agreements with AstraZeneca UK Limited and Astellas Pharma Inc. or Regeneron's November 2007 collaboration agreement with sanofi-aventis. Moreover, due to other considerations in the agreement, no royalties are payable on any revenue from commercial sales of antibodies from Regeneron's VelocImmune technology.

Regeneron and Cellectis also entered into a Subscription Agreement pursuant to which Regeneron will acquire 368,301 ordinary shares of Cellectis, par value EUR 0.05 per share, at a price of EUR 8.63 per share, for a total of EUR 3,178,437.63. The subscription is contingent upon the prior approval of the board of directors of Cellectis and by the shareholders of Cellectis at an extraordinary gen
'/>"/>

SOURCE Cellectis SA
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
2. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
10. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...ected to aid drug discovery by allowing for the ra...gle reaction, ST. LOUIS, Oct. 7 /PRNewswire-First...o announce that it has signed an exclusive licensi...bana-Champaign allowing,Sigma-Aldrich to offer res...ogates for use in Suzuki-Miyaura coupling to resea...
(Date:10/7/2008)...s to focus on new patient data supporting the Ross...ynerGraft processed human heart .../- CryoLife, Inc. (NYSE: C...ocessing company, announced today,that cardiovascu...e in the,Ross Summit 2008, a two-day surgical cong...
(Date:10/7/2008)...Institutes of Health, The Infectious Disease Resea...Launch and Board of Advisors, SEATTLE, Oct. 7 /PR...,Initiative today announced its first acquisition ...osis (TB) drug candidates. Agreements were reached...nd the Microbial Chemistry,Research Foundation (MC...
(Date:10/7/2008)... Oct. 7 /- BioEnergy International, L...r and manufacturer of,next-generation, renewable b...f Norman R. Augustine to its Board of Advisors eff...f distinguished leadership and innovation,at the h...g in his role as,Chairman and Chief Executive Offi...
Breaking Biology Technology:Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 2CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 2Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 3Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 5BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 3
...eenah, Wis. - Thanks to a classified contract fro...alization company headquartered here, reported rec...rter ended July 1, 2006, despite the closing of it...y,s financial picture is tempered, however, by for...th quarter, which caused its stock price to fall b...
...ditor,s note: This article first appeared in Gene...ere is good news for inventors. Using an invention...ger than a year, will not by itself cause a court ...invention. , ,This rule was pronounced in response...nt asserted that the patent was invalid due to pri...
...auwatosa, Wis. - Personalized medicine is a conce...but people in the know believe so-called genetic-b...ic-based medicine, personal genetic profiles will ...o various diseases, and to develop disease managem...vironmental characteristics. , , Stephens Crack...
... shkosh, Wis. - BidRx , a new online company th...iption medications, is attempting to create a new ... has gone live with its new web site, where consum...are costs and obtain other information about presc...e for their medications out of pocket, the site,s ...
Other Biology Technology:Defense contract helps Plexus gain record profits 2With patents and research tools, when is private really public? 2With patents and research tools, when is private really public? 3With patents and research tools, when is private really public? 4With patents and research tools, when is private really public? 5Medical College researcher working to make genetic-based medicine a reality 2Medical College researcher working to make genetic-based medicine a reality 3Will BidRx start a drug price war? 2Will BidRx start a drug price war? 3Will BidRx start a drug price war? 4
(Date:10/7/2008)...nsional. That,s true even in the laboratory, where...evelop and what happens when their growth is abnor...o develop three-dimensional cell culture systems t...ugs in a system that more closely mimics the way i...is the cost of commercial media for growing such c...
(Date:10/7/2008)... Li Lab has characterized a mechanism that allows ...ocytes. By tracking chromosome movement in live mo...can recruit to their vicinity a protein called for...e majority of the cytoplasm a requirement for emb...other daughter cell (called a polar body) resultin...
(Date:10/7/2008)... 2008 Burnham Institute for Medical Research toda... that binds to Bcl-2, a protein that protects canc...it into a cancer cell killer. The research, which ...er 7 edition of Cancer Cell , may lead to new can...n implicated in protecting cancer cells from apopt...
(Date:10/6/2008)...mption of red wine may decrease the risk of lung c... issue of Cancer Epidemiology, Biomarkers & Preve...ancer Research. , "An antioxidant component in ...larly among smokers," said Chun Chao, Ph.D., a res...of Research and Evaluation in Pasadena, California...
Breaking Biology News(10 mins):Egg whites solve the 3-D problem 2Red wine may lower lung cancer risk 2ULURU Inc Announces the Launch Plan for Altrazeal 28TM 29 18793 1ULURU Inc Announces the Launch Plan for Altrazeal 28TM 29 18793 2ULURU Inc Announces the Launch Plan for Altrazeal 28TM 29 18793 3Susan G Komen for the Cures 28R 29 Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 18788 1Susan G Komen for the Cures 28R 29 Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 18788 2Susan G Komen for the Cures 28R 29 Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 18788 3Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 1Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 2Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 3Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 4Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 5Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 6Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 7Scientists identify key roadblock to gene expression 18781 1Scientists identify key roadblock to gene expression 18781 2
...itive tissue throughout the body have an undesirab...ions away. To overcome this hurdle, Johns Hopkins ... with a chemical that helps them slip through this...e coated particles, the researchers also discovere...eviously thought, providing a doorway that should ...
... able to eat prawns without the fear of an adverse...ng step towards removing from prawns the proteins ...to genetic manipulation, reports Lisa Richards in ... , Li Zhenxing led the research at the Ocean Unive...awns with a combination of heat and irradiation si...
...ty School of Medicine has helped confirm the reli...shering in the long-promised era of personalized .... , The Stanford group was one of the five sites t...entify patients who are at high risk of developin...at means high-risk patients could be directed tow...
...ill reveal in the 29 March 2007 issue of the journ...of important structures that control how genes are...e. "For the first time, we are seeing in very hig...s control the expression of an organism,s genes," ...nd molecular biology and the study,s lead investig...
Other Biology News:Coated nanoparticles solve sticky drug-delivery problem 2Coated nanoparticles solve sticky drug-delivery problem 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3Scientists reveal structure of gateways to gene control 2Scientists reveal structure of gateways to gene control 3Scientists reveal structure of gateways to gene control 4
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface.
Antibeta-lactoglobulin monoclonal antibody(CD-2)
MAb to Vasopressin Preservative: NaN3
...α, clone 8G8/5 GenBank Accession Number : N...lpha/gamma fusion protein corresponding to residue...0 of human AP-2γ Formulation: 0.1M Tris-glyc... the addition of glycerol to 30% Quality Assurance...
Biology Products: